DICE Therapeutics
Neeraj Koduri is currently working as the Business Development & Strategy Lead at DICE Therapeutics since March 2021. Prior to this role, Neeraj worked as a Biotech Equity Research Associate at Evercore from February 2019 to March 2020, focusing on Small/Mid-Cap Biotechnology. Neeraj also served as an Investment Banking Analyst at Wells Fargo Securities from June 2017 to February 2019 within the Healthcare Group (Life Sciences). Neeraj has a background in portfolio management and trading, having been the Portfolio Manager & Trader at USC Undergraduate Student Investment Fund from April 2016 to April 2017. Neeraj holds a degree in Business Administration with a focus on Biotechnology from the University of Southern California.
This person is not in any teams
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.